[en] This document seeks to provide guidance in planning and in reviewing proposals for NMR services in the region, until a quantitative need assessment for those services can be developed. The Food and Drug Administration's determination that the diagnostic capabilities of NMR imaging have proven to provide substantial benefit vs. risk to patients proven by scientifically valid studies conducted by sponsors of investigational equipment at hospital sites, is pending. When the costs and benefits are clarified, then standards and criteria and a need assessment method, both on the institutional and regional levels, will be developed as an amendment to the Health Systems Plan